Autistic children have long been known to have differences in their gut microbiota and as a result are more...

Axial Therapeutics announced completion of enrollment in the TAPESTRY Autism Study, the Phase 2b clinical trial of its lead...

Axial Therapeutics announced it has received a research grant from The Michael J. Fox Foundation for Parkinson’s Research (MJFF)...

Axial Therapeutics announced it is expanding the age eligibility criterion to include children ages 5 to 17 years in...

Axial Therapeutics announced key promotions in its research and development organization. These promotions recognize the Axial team’s scientific and...

A new trial sponsored by Axial Therapeutics will test whether a medication that targets gut bacteria can also improve...

Axial Therapeutics announced that A. Stewart Campbell, Ph.D., chief executive officer, will give a presentation titled, “Targeting Bacterial Metabolites...

Axial Therapeutics announced that it is building on its clinical development science and operations capabilities through recent key appointments....

Axial Therapeutics Inc. announced that A. Stewart Campbell, Ph.D., Chief Executive Officer, will present in two seminars at BioJapan...

Axial Therapeutics announced that A. Stewart Campbell, Ph.D., will participate in a panel entitled “The Next Wave of Targeted...